Green Light for Kids' COVID Jab Using Rare Disease Fast-Pass
Published Date: 4/16/2026
Notice
Summary
The FDA just gave the green light to MNEXSPIKE, a COVID-19 vaccine, using a special Rare Pediatric Disease Priority Review Voucher. This means the vaccine got a faster review because it helps kids with rare diseases. The approval happened on May 30, 2025, and this move speeds up access to important treatments for children who need them most.
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Pediatric COVID Vaccine Approved Faster
If you have a child with a rare pediatric condition, the FDA approved MNEXSPIKE (a COVID-19 mRNA vaccine) on May 30, 2025 using a Rare Pediatric Disease Priority Review Voucher. That voucher means the vaccine received a faster review so it can reach children who need it sooner.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in